| Aug 11 |
Investors in AnaptysBio (NASDAQ:ANAB) have seen respectable returns of 74% over the past year
|
| Aug 5 |
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 5 |
AnaptysBio GAAP EPS of -$1.71 misses by $0.67, revenue of $10.97M misses by $11.79M
|
| Aug 1 |
GSK wins FDA nod to expand Jemperli label in uterine cancer
|
| Jul 30 |
Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
| Jul 22 |
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
|
| Jul 22 |
Is HCA Healthcare (HCA) Stock Outpacing Its Medical Peers This Year?
|
| Jul 8 |
AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)
|
| Jun 24 |
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
|
| May 22 |
Industry Analysts Just Upgraded Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts By 16%
|
